What is the CVSS score of CVE-2023-33366?

CVE-2023-33366 has a CVSS 3.1 base score of 8.8 (High). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H. EPSS exploitation probability: 0.6%.

Biostar 2 CVE-2023-33366

HIGH

SQL Injection (CWE-89)

2023-08-03 cve@mitre.org

SQLi Biostar 2

8.8

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

8.8 HIGH

AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Attack Vector

Network

Attack Complexity

Low

Privileges Required

Low

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

High

Availability

High

Lifecycle Timeline

CVE Published

Aug 03, 2023 - 16:15 nvd

HIGH 8.8

DescriptionNVD

A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject arbitrary SQL directives into an SQL statement and execute arbitrary SQL commands.

AnalysisAI

A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject arbitrary SQL directives into an SQL statement and execute arbitrary SQL commands. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as SQL Injection (CWE-89), which allows attackers to execute arbitrary SQL commands against the database. A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject arbitrary SQL directives into an SQL statement and execute arbitrary SQL commands. Affected products include: Supremainc Biostar 2. Version information: before 2.9.1.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Use parameterized queries/prepared statements. Never concatenate user input into SQL. Apply least-privilege database permissions.